We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Buy Beaten-Down Walgreens (WBA) Stock Ahead of Earnings?
Read MoreHide Full Article
Walgreens Boots Alliance (WBA - Free Report) reports its Q3 fiscal 2020 financial results before the opening bell on Thursday, July 9. The question is should investors consider buying shares of the struggling pharmacy chain?
Walgreens stock has taken a big hit over the last several years as Wall Street worries the pharmacy retailer will struggle down the road in a quickly changing retail environment. This includes Amazon’s (AMZN - Free Report) expanded pharmacy business, as well as Target (TGT - Free Report) and Walmart 's (WMT - Free Report) continued e-commerce growth. The company is also under pressure to diversify after the CVS and Aetna (CVS - Free Report) merger.
With this in mind, WBA shares are down 3% since March 23, while the S&P 500 surged over 40% and rival CVS jumped 20%. More broadly, Walgreens stock has fallen 45% over the last three years, as Wall Street worries about prescription drug delivery disruption, a possible lack of in-store foot traffic, and more.
WBA topped Q2 estimates for the period ended on Feb. 29, but it said that its U.S. store sales fell sharply in the last week of March, after an initial stockpiling surge. The pharmacy chain noted that it is diverting some funds for its restructuring plans to help with coronavirus-based costs.
Looking ahead, our Zacks estimates call for WBA’s adjusted Q3 earnings to fall 27% to $1.08 a share, on 1.7% lower revenue. This would mark its first year-over-year sales decline since the second quarter of 2017. Walgreens has also seen its earnings estimates trend lower over the last seven days, with Q3 down from $1.15 to $1.08 a share.
Walgreens is currently a Zacks Rank #4 (Sell), with an “F” grade for Momentum in our Style Scores system. Despite its strong dividend yield and beaten-down price point, investors likely want to stay away, at least until WBA stock shows some signs of a comeback.
Zacks’ Single Best Pick to Double
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This young company’s gigantic growth was hidden by low-volume trading, then cut short by the coronavirus. But its digital products stand out in a region where the internet economy has tripled since 2015 and looks to triple again by 2025.
Its stock price is already starting to resume its upward arc. The sky’s the limit! And the earlier you get in, the greater your potential gain.
Buy Beaten-Down Walgreens (WBA) Stock Ahead of Earnings?
Walgreens Boots Alliance (WBA - Free Report) reports its Q3 fiscal 2020 financial results before the opening bell on Thursday, July 9. The question is should investors consider buying shares of the struggling pharmacy chain?
Walgreens stock has taken a big hit over the last several years as Wall Street worries the pharmacy retailer will struggle down the road in a quickly changing retail environment. This includes Amazon’s (AMZN - Free Report) expanded pharmacy business, as well as Target (TGT - Free Report) and Walmart 's (WMT - Free Report) continued e-commerce growth. The company is also under pressure to diversify after the CVS and Aetna (CVS - Free Report) merger.
With this in mind, WBA shares are down 3% since March 23, while the S&P 500 surged over 40% and rival CVS jumped 20%. More broadly, Walgreens stock has fallen 45% over the last three years, as Wall Street worries about prescription drug delivery disruption, a possible lack of in-store foot traffic, and more.
WBA topped Q2 estimates for the period ended on Feb. 29, but it said that its U.S. store sales fell sharply in the last week of March, after an initial stockpiling surge. The pharmacy chain noted that it is diverting some funds for its restructuring plans to help with coronavirus-based costs.
Looking ahead, our Zacks estimates call for WBA’s adjusted Q3 earnings to fall 27% to $1.08 a share, on 1.7% lower revenue. This would mark its first year-over-year sales decline since the second quarter of 2017. Walgreens has also seen its earnings estimates trend lower over the last seven days, with Q3 down from $1.15 to $1.08 a share.
Walgreens is currently a Zacks Rank #4 (Sell), with an “F” grade for Momentum in our Style Scores system. Despite its strong dividend yield and beaten-down price point, investors likely want to stay away, at least until WBA stock shows some signs of a comeback.
Zacks’ Single Best Pick to Double
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This young company’s gigantic growth was hidden by low-volume trading, then cut short by the coronavirus. But its digital products stand out in a region where the internet economy has tripled since 2015 and looks to triple again by 2025.
Its stock price is already starting to resume its upward arc. The sky’s the limit! And the earlier you get in, the greater your potential gain.
Click Here, See It Free >>